Growth-Hormone Secretagogue Comparison Guide for Canadian Research Buyers

Quick answer: the GH secretagogue comparison table#

A growth-hormone secretagogue comparison is useful only when it separates three things that supplier pages often blend together: receptor lane, exposure profile, and research endpoint. For the non-secretagogue myostatin lane, use the myostatin pathway map for Follistatin research before comparing GH-axis compounds. If those are not separated, CJC-1295, Sermorelin, Ipamorelin, Tesamorelin, GHRP-6, GHRP-2, Hexarelin, and MK-677 all collapse into the same vague category: “GH peptides.” That is not good enough for research procurement.

For Canadian research buyers, the better question is: which GH-axis material best matches the model, sampling window, comparator set, and batch-documentation standard?

The table is not a ranking. A ranked list optimises for affiliate-style buyer intent. A research comparison optimises for fewer category errors. A short GHRH fragment, an albumin-binding GHRH analogue, a ghrelin-receptor peptide, and a non-peptide oral agonist may all move GH-axis endpoints in some settings, but they are not interchangeable tools. The same rule excludes myostatin-pathway materials: Follistatin-344 belongs in activin/myostatin ligand-sequestration research, not in a GH-secretagogue comparison table. If that is the material under review, use the Follistatin-344 COA and isoform verification checklist before applying generic GH-axis supplier logic.

For a current live-product inspection path, keep the comparison tied to available lot documentation rather than generic catalogue language: CJC-1295 without DAC, CJC-1295 with DAC, Sermorelin, Ipamorelin, and Tesamorelin are the relevant LynxLabs records to inspect from this guide. GHRP-6, GHRP-2, Hexarelin, and MK-677 stay as literature/context rows unless a current verified product record exists; Northern Compound should not route readers toward unavailable materials or raw store URLs.

If the immediate problem is supplier quality rather than mechanism, start with the peptide COA verification checklist, the peptide storage and vial inspection checklist, the research peptide supplier scorecard, and the batch documentation template. When the selected GH-axis material is lyophilised, add the peptide reconstitution record field matrix before comparing handling assumptions across CJC, Sermorelin, Ipamorelin, Tesamorelin, or GHRP records. If the problem is GH-axis category design, use this guide alongside the GH pulsatility research guide, the ghrelin receptor peptide guide, and the growth-hormone peptides overview.

This article is research-use-only editorial context. It does not provide medical advice, diagnosis, dosing, administration instructions, hormone-replacement advice, anti-ageing guidance, bodybuilding-cycle advice, or personal-use recommendations.

Why this asset exists#

Northern Compound already has dedicated guides for individual GH-axis compounds. That is useful for high-intent searches, but it creates a second need: a linkable, citation-friendly comparison page that explains how to choose the right lane before choosing a product page.

The GH secretagogue category is especially prone to sloppy comparisons because several true statements can be arranged into a weak conclusion. It can be true that a compound stimulates growth hormone in a particular model. It can be true that another compound raises IGF-1 under a different exposure profile. It can be true that a clinical drug has a narrow approved history. It does not follow that all of them are equivalent “anti-ageing peptides,” “recovery peptides,” or “GH boosters.”

The scientific literature supports more precise distinctions. Reviews of growth-hormone secretagogues describe a broad family that includes GHRPs and small molecules, with attention to GH release, IGF-1, ghrelin-receptor biology, appetite, ageing-related endocrine questions, and therapeutic-development possibilities (Miller and Bowers, 2017). CJC-1295 literature describes an albumin-binding GHRH analogue designed for prolonged exposure (PubMed, PubMed). Ipamorelin literature highlights a selective GH secretagogue profile relative to older GHRPs in early endocrine models (Raun et al., 1998). Tesamorelin has a regulated-drug history in HIV-associated lipodystrophy, which is narrower than the broad wellness claims often seen online (FDA label).

Those sources are useful because they force the comparison back to mechanism and context. They do not justify human-use instructions for research-grade vials. They do not create a dosing table. They do not turn supplier pages into medical guidance. This page is designed to be a safer asset: a receptor-and-documentation map that other GH-axis posts can link to when a reader needs a clean overview.

The two main lanes: GHRH side versus GHSR side#

The first split is receptor lane.

GHRH-side compounds act through the growth hormone-releasing hormone pathway. Sermorelin, CJC-1295 without DAC, CJC-1295 with DAC, and Tesamorelin belong here, though they differ in sequence, stability, exposure, and regulatory history. The research question usually concerns GHRH-receptor stimulation, pituitary somatotroph responsiveness, GH pulse shape, IGF-1 movement, or clinical-reference comparators.

GHSR-side compounds act through the growth hormone secretagogue receptor, also known as the ghrelin receptor. Ipamorelin, GHRP-6, GHRP-2, Hexarelin, and MK-677 belong in this wider lane, although MK-677 is not a peptide. The research question usually concerns ghrelin-receptor biology, GH secretagogue signalling, appetite or motility confounding, HPA-axis spillover, or sustained versus acute GHSR exposure.

That split matters because the GH axis is not a single switch. GHRH, somatostatin, ghrelin, sleep state, nutrition, stress physiology, sex steroids, age, disease models, assay timing, and IGF-1 feedback all shape the observed signal. A compound can stimulate one input while the surrounding system determines whether the endpoint is detectable or interpretable.

A clean comparison starts with a sentence like this: “This protocol is testing a short GHRH-receptor pulse,” or “This supplier review is comparing GHSR agonist documentation,” or “This article is mapping sustained albumin-bound GHRH analogue exposure against shorter GHRH fragments.” If the sentence cannot be written, the comparison is premature.

Exposure profile: pulse, sustained signal, or non-peptide agonism#

The second split is exposure profile.

A short peptide stimulus and a long-acting analogue can both sit in the GH category while creating different experiments. Sermorelin is the historical GHRH(1-29)-NH2 fragment reference point. CJC-1295 without DAC is a modified GHRH analogue generally discussed around shorter GHRH-side signalling and pulsatility. CJC-1295 with DAC introduces an albumin-binding drug affinity complex concept that extends exposure. A protocol that substitutes DAC material into a short-pulse design has changed the study, not just the catalogue item.

The same issue appears on the GHSR side. Ipamorelin is usually discussed as a selective GH secretagogue peptide. GHRP-6 is an older GHRP comparator where appetite and broader endocrine signals can matter. MK-677 is a non-peptide oral GHSR agonist with a sustained exposure profile. It can be useful as literature context, but it is not a peptide substitute and should not be handled as if a peptide COA framework answers all questions.

Exposure changes sampling. GH secretion is pulsatile. A poorly timed blood draw can miss the signal. A sustained analogue can change baseline, feedback, and downstream IGF-1 interpretation. A non-peptide agonist can bring route and duration questions that do not apply to a lyophilised peptide vial. A comparison table that ignores timing is usually a marketing table, not a research tool.

Endpoint-first selection guide#

The most practical way to use a GH secretagogue comparison is to begin with the endpoint, then choose the candidate lane.

This endpoint-first framing prevents a common editorial failure: selecting the compound because it is popular, then backfilling the rationale with loosely related literature. If the model question is acute GHRH responsiveness, a GHSR agonist may be the wrong first choice. If the model question is older-GHRP endocrine spillover, a clean GHRH fragment will not answer it. If the model question is supplier documentation, the literature is not enough; the current batch record becomes part of the evidence.

Compound-by-compound notes for Canadian research buyers#

Sermorelin#

Sermorelin is best treated as the GHRH(1-29)-NH2 reference compound. Its value is interpretive clarity. It asks a GHRH-receptor question and helps separate short GHRH fragment biology from modified analogue biology.

For Canadian research buyers, the documentation burden is specific: the product page should support the expected GHRH(1-29)-NH2 identity, terminal amidation, expected mass, purity, lot number, fill amount, storage conditions, and RUO status. A generic “GHRH peptide” listing is weaker than a listing that states the molecule plainly.

The main overclaim risk is turning GHRH-axis stimulation into personal hormone-replacement or anti-ageing advice. A research article can discuss Sermorelin as an axis probe. It should not suggest that research-grade material treats growth-hormone deficiency, reverses ageing, improves sleep, changes body composition, or belongs in a personal protocol.

Use the dedicated Sermorelin Canada guide when the reader needs a deeper explanation of GHRH(1-29)-NH2 and its distinction from CJC analogues.

CJC-1295 without DAC#

CJC-1295 without DAC is commonly discussed as Modified GRF (1-29), a shorter-acting modified GHRH analogue. Its practical value is timing control. It belongs in comparisons where the protocol needs a GHRH-side stimulus without the extended albumin-bound exposure of DAC material.

The key procurement question is whether the supplier clearly distinguishes no-DAC material from DAC material. The label should not force the buyer to guess. The COA should support identity, expected mass, purity, lot match, and storage. If the page simply says “CJC-1295” without DAC status, the documentation is incomplete for research use.

The overclaim risk is subtle: no-DAC material is often sold as a stack component, and stack language can drift quickly into personal-use optimization. Northern Compound’s framing is narrower. Separate CJC-1295 without DAC and Ipamorelin pages can be inspected for current documentation, but a product link is not a protocol recommendation.

Use the CJC-1295 without DAC guide and GH pulsatility guide when timing and sampling assumptions matter.

CJC-1295 with DAC#

CJC-1295 with DAC is the extended-exposure member of the CJC family. The drug affinity complex concept is not a branding flourish; it changes the experiment by extending exposure through albumin-binding biology. Published CJC-1295 work describes prolonged GH and IGF-1 stimulation and persistent pulsatile GH secretion during continuous stimulation (PubMed). Early analogue work identified albumin-binding bioconjugate behaviour (PubMed).

That makes DAC material useful when the question is sustained GHRH-analogue exposure. It also makes it a poor substitute when the protocol expects a short pulse. A buyer comparing DAC and no-DAC material should write down the sampling schedule before comparing product pages.

QC should confirm DAC identity, not merely “CJC-1295.” A supplier that hides DAC status or fails to document the current lot is asking the buyer to accept a major pharmacokinetic assumption on faith.

Ipamorelin#

Ipamorelin belongs on the GHSR side. Its strongest research identity is comparative selectivity. The classic endocrine paper described Ipamorelin as a selective GH secretagogue and compared it with older GHRPs, reporting GH stimulation without the same ACTH and cortisol release profile in that model (Raun et al., 1998).

That is a useful distinction, not a blanket safety claim. “Selective” means selective relative to specified comparators, in specified models, with specified endpoints. It does not mean clinically approved for anti-ageing use, free of broader receptor biology, or appropriate for personal use.

For procurement, Ipamorelin should have declared sequence or chemical identity, expected mass, purity evidence, fill amount, storage conditions, and RUO language. If a page leans heavily on “clean,” “gentle,” or “best” without showing batch documentation, the marketing is doing work the COA should do.

Use the Ipamorelin Canada guide and ghrelin receptor peptide guide when the reader needs deeper GHSR context.

Tesamorelin#

Tesamorelin is a stabilised GHRH analogue with a specific regulated-drug history. The FDA-approved product label is tied to reducing excess abdominal fat in HIV-infected patients with lipodystrophy, not to broad anti-ageing, bodybuilding, or wellness claims (FDA label).

That regulatory history makes Tesamorelin valuable as a clinical-reference comparator. It also raises the compliance bar. A research article can say that Tesamorelin has a specific approved-drug context and has been studied in metabolic-endpoint settings. It should not generalise that context into personal fat-loss advice or imply that RUO material is interchangeable with regulated medicine.

For Canadian buyers, source and legal-use framing matter as much as identity. The Tesamorelin Canada guide covers the narrower molecule-specific context.

GHRP-6 and older GHRP context#

GHRP-6 is useful when the question involves older GHRP/GHSR biology, appetite-related signalling, or broader endocrine spillover. It is less useful when a protocol wants the cleanest possible GH-only interpretation. Older GHRP comparisons matter precisely because GH, ACTH, cortisol, prolactin, appetite, and ghrelin-receptor effects can all complicate the readout.

GHRP-2 and Hexarelin are also relevant to the literature, but they should be handled carefully in Northern Compound content because potency can blur into overclaiming faster than with cleaner GHRH-side comparisons. Use the dedicated GHRP-2 guide and Hexarelin Canada guide for molecule-specific context before treating either as a generic “stronger secretagogue.” That keeps the article honest about what is mechanism context, what is supplier inspection, and what remains a research-design decision.

The overclaim risk in older GHRP content is equating potency with quality. A potent secretagogue may produce a larger signal and a messier endpoint. Stronger is not automatically cleaner.

MK-677 / ibutamoren context#

MK-677, also known as ibutamoren, is frequently grouped with GH secretagogues because it is a non-peptide oral GHSR agonist. That grouping is useful for receptor context and dangerous for procurement. It is not a peptide. It does not belong in a peptide vial comparison. It should not be linked as a live peptide product when the destination is unavailable.

MK-677 literature can help explain sustained GHSR/GH/IGF-1 exposure questions. It should not be used to imply that short peptides behave like oral small molecules, or that route and duration are minor details. In this guide, MK-677 remains mechanism context only.

Canadian supplier-quality checklist#

Use this checklist before treating any GH secretagogue product page as research-ready:

• Lot-specific COA: the batch number on the COA should match the vial, product page, and order record.
• Identity evidence: the COA should support expected mass, sequence or chemical identity, salt/form details where relevant, and DAC status where relevant.
• Purity method: HPLC or UPLC purity should include enough chromatogram or method context to make the number auditable.
• Fill amount: vial content should be stated clearly and traceable to the lot.
• Storage language: lyophilised and reconstituted handling expectations should be documented without becoming human-use instructions; use the peptide reconstitution guide for solvent, concentration, labelling, and freeze-thaw vocabulary.
• Test date: stale or recycled COAs weaken confidence, especially in a fast-changing supplier catalogue.
• RUO boundary: supplier copy should avoid treatment, dosing, injection, anti-ageing, bodybuilding, weight-loss, or disease claims.
• Product-page specificity: CJC listings should state DAC status; Sermorelin should state GHRH(1-29)-NH2 identity; blends should state component identities and ratio if they exist.
• Live destination: ProductLink paths should resolve to current Lynx pages or safe fallback destinations, never raw dead product URLs.
• Internal record: the buyer should preserve the COA, product screenshot, order record, storage log, and protocol rationale.

A high purity number does not prove suitability for human use. It does not prove clinical efficacy. It does not prove the supplier’s claims are appropriate. It only supports one part of the research-material quality screen.

Decision tree for choosing the right GH-axis page#

Step 1: Name the receptor lane. If the question is GHRH-receptor stimulation, start with Sermorelin, CJC-1295 without DAC, CJC-1295 with DAC, or Tesamorelin. If the question is GHSR or ghrelin-receptor signalling, start with Ipamorelin, GHRP-6, or older GHRP literature.

Step 2: Name the time profile. If the endpoint is an acute pulse, short-acting GHRH-side tools or selective GHSR-side tools may be relevant. If the endpoint is sustained GH/IGF-1 exposure, DAC material, Tesamorelin context, or non-peptide GHSR literature may be relevant. Do not mix those designs without stating why.

Step 3: Name the primary endpoint. GH, IGF-1, appetite behaviour, motility, ACTH, cortisol, prolactin, glucose/insulin markers, tissue-level readouts, and supplier-documentation readiness are different endpoints. Pick one primary endpoint before selecting a compound.

Step 4: Pick comparators that answer the question. Sermorelin versus CJC-1295 without DAC answers a GHRH-fragment versus modified-fragment question. CJC no-DAC versus DAC answers a time-profile question. Ipamorelin versus GHRP-6 answers a GHSR selectivity and endocrine-spillover question. Tesamorelin versus research-market analogues answers a clinical-reference and regulatory-context question.

Step 5: Audit the current lot. After the biology is coherent, inspect the current supplier documentation. Do not let a product page choose the research question.

Compliance boundaries for GH secretagogue content#

GH-axis content attracts aggressive claims. Northern Compound avoids those claims because they are usually where evidence quality, legal status, and reader safety become muddled.

A compliant article can say that growth-hormone secretagogues include peptide and non-peptide compounds that stimulate GH release through different receptor systems. It can say that GHRH-side and GHSR-side materials should be compared by mechanism. It can discuss published endocrine, pharmacokinetic, and regulatory-context literature. It can route readers to live product pages for current documentation review using UTM-attributed ProductLink components.

It should not say that research-grade GH secretagogues treat growth-hormone deficiency, reverse ageing, improve body composition, build muscle, repair sleep, cure disease, treat lipodystrophy, heal injuries, or belong in personal protocols. It should not provide human dosing, cycle timing, injection guidance, titration, stacking instructions, or medical monitoring advice. It should not borrow a regulated-drug label and paste it onto RUO catalogue material.

The strongest buyer-intent content is not the most permissive content. It is the content that helps a reader make fewer bad assumptions.

Research-note worksheet for comparing two GH-axis candidates#

When two growth-hormone secretagogue candidates both look plausible, write a short research note before opening product pages. This keeps the comparison anchored to the model instead of the catalogue.

A strong worksheet can be brief. The point is not bureaucracy. The point is to stop a common GH-axis mistake: choosing a product name first, then treating every paper in the surrounding category as support for that choice.

For example, a comparison between CJC-1295 without DAC and CJC-1295 with DAC should not begin with which one is “stronger.” It should begin with whether the model requires a discrete GHRH-side pulse or a longer albumin-bound exposure profile. A comparison between Ipamorelin and GHRP-6 should not begin with which one is “better.” It should begin with whether older-GHRP endocrine spillover, appetite signalling, ACTH, cortisol, or prolactin are part of the question.

The worksheet also protects supplier review. If the note says the protocol requires DAC material, a CJC listing that does not explicitly document DAC status is not merely incomplete; it fails the comparison. If the note says the protocol requires a short GHRH-fragment reference, a long-acting analogue does not become acceptable because the price or product page looks better. If the note says the protocol requires a GHSR selectivity comparison, a GHRH-side product cannot answer it.

Protocol triage card: choose the lane before opening supplier pages#

Use this triage card when a broad search query such as “CJC vs Ipamorelin,” “best GH secretagogue,” or “growth hormone peptides Canada” needs to become a defensible research note. It is deliberately short enough to copy into an internal procurement record, but strict enough to stop the common category errors.

A useful completed card might say: “GHRH-side, acute pulse, primary endpoint serial GH sampling, comparator Sermorelin, required evidence no-DAC identity plus mass confirmation, claim boundary no human hormone-optimization inference.” That sentence is far stronger than “compare CJC and Ipamorelin,” because it names the mechanism, timing, endpoint, source requirement, and compliance line.

If the card cannot be completed, the buyer is not ready for a product page. Start with the GH pulsatility guide for timing, the COA verification checklist for documents, and this comparison guide for receptor-lane sorting.

Supplier scorecard for GH secretagogue comparisons#

A scorecard is useful only if it rewards documentation and penalises overclaiming. Northern Compound would not score a GH-axis supplier by “strongest” language, testimonial volume, or protocol promises. Those signals usually increase compliance risk.

The scorecard should be used as a rejection filter, not as a medical ranking. A supplier can score well on identity and still be unsuitable for a specific protocol if the receptor lane or exposure profile is wrong. A supplier can also have a clean product page and still require current COA review before any lot is used.

For current Lynx inspection paths, use ProductLink components for live materials only: Sermorelin, CJC-1295 without DAC, CJC-1295 with DAC, Ipamorelin, Tesamorelin, and GHRP-6. Treat GHRP-2, Hexarelin, MK-677, and other unavailable or non-peptide terms as mechanism context unless a current live destination has been verified.

Linkable-asset notes for editors and researchers#

This page is designed to be cited when a reader needs a neutral map of the GH-axis category rather than another product-specific claim. The best inbound links should point to the comparison logic, not to a promise about outcomes. If another article is discussing CJC-1295 versus Sermorelin, the relevant anchor is the GHRH-side comparison. If another article is discussing Ipamorelin versus GHRP-6, the relevant anchor is the GHSR-side and endocrine-spillover comparison. If another article is discussing supplier due diligence, the relevant anchor is the scorecard or COA checklist.

Editors should avoid using this asset as a shortcut for claims the asset itself does not make. A clean internal-link sentence might read: “Before comparing GH-axis suppliers, separate receptor lane, exposure profile, endpoint, and batch documentation using the growth-hormone secretagogue comparison guide.” A weaker sentence would say: “Use this guide to find the best GH peptide.” The first sentence helps readers think; the second sentence drifts toward affiliate ranking language.

Researchers can use the page in three practical ways. First, as a pre-procurement screen: write the receptor lane, exposure hypothesis, endpoint, comparator, and minimum COA evidence before opening product pages. Second, as a review checklist: if a paper or supplier page moves from GH or IGF-1 endpoints to anti-ageing, body-composition, sleep, recovery, or wellness language without direct evidence, mark the claim boundary. Third, as an internal documentation aid: save the completed triage card beside the COA, product screenshot, storage record, and protocol rationale so the material decision can be audited later.

The asset also protects the archive from over-linking. A molecule-specific guide should still be the destination when the reader needs detail on one compound. This comparison guide should be the destination when the sentence crosses lanes, compares exposure profiles, or explains why a live product page is not the same thing as a protocol recommendation. That division keeps Northern Compound useful for search while preserving a conservative RUO posture.

Common sourcing mistakes this comparison should prevent#

The first mistake is shopping by category label. A supplier menu may place CJC-1295, Sermorelin, Ipamorelin, GHRP-6, Tesamorelin, and HGH under a growth-hormone heading because that is convenient navigation. Navigation is not mechanism. A research buyer should translate the menu into receptor lane, exposure profile, endpoint, and documentation requirements before comparing prices or claims.

The second mistake is ignoring DAC status. “CJC-1295” is not precise enough for serious work. DAC status changes exposure, sampling, interpretation, and sometimes the entire endpoint hierarchy. A page that does not identify the variant clearly should be treated as a documentation problem, not as a minor naming issue.

The third mistake is turning selectivity into safety language. Ipamorelin’s selective positioning is scientifically interesting because it helps compare GH release with older-GHRP endocrine signals in defined models. It does not prove safety for personal use, does not create an approved clinical indication, and does not erase the broader biology of GHSR signalling.

The fourth mistake is using clinical-reference compounds as marketing shortcuts. Tesamorelin’s regulated-drug history is relevant because it gives the archive a real clinical comparator. That history should make the article more careful, not less careful. It does not justify applying a narrow drug label to RUO catalogue material or to unrelated wellness claims.

The fifth mistake is over-reading IGF-1. IGF-1 can be a useful downstream marker, especially for sustained GH-axis exposure, but it cannot by itself prove physiological GH pulsatility, tissue-specific benefit, or human outcome. If the claim is about pulse architecture, serial GH data matter. If the claim is about tissue response, tissue endpoints matter. If the claim is about source quality, COA evidence matters.

The sixth mistake is linking unavailable products as if they are live options. Northern Compound can discuss GHRP-2, Hexarelin, and MK-677 as literature context where relevant, but dead or uncertain Lynx product slugs should not be used as conversion paths. The honest route is to describe the comparison term, then link only to live or safely handled ProductLink destinations for current documentation review.

How this asset supports internal navigation#

This page is meant to sit between the broad growth-hormone archive and the molecule-specific guides. A reader who arrives at the growth-hormone peptides overview can use this page to decide which lane matters. A reader who arrives at the Sermorelin guide can use it to understand why GHRH fragments differ from GHSR peptides. A reader who arrives at the Ipamorelin guide can use it to separate selective GHSR framing from CJC and Sermorelin comparisons.

The same logic helps older posts. The CJC-1295 without DAC guide needs a cross-link whenever DAC status, short-pulse timing, and GHSR pairing questions appear together. The CJC-1295 DAC guide needs a cross-link whenever sustained exposure is being compared with shorter GHRH tools. The GH pulsatility guide needs a cross-link because pulse architecture is one of the easiest places for GH-axis content to overclaim.

That internal role is why this article uses tables, a decision tree, a worksheet, and sourcing red flags rather than a simple “best peptide” list. It is a linkable asset, not just another compound guide. Its job is to absorb broad comparison intent and route readers into the right deeper page without weakening RUO boundaries.

Example comparison scenarios#

Scenario 1: a buyer is comparing Sermorelin and CJC-1295 without DAC. The clean question is not which one is more popular. The clean question is whether the protocol needs the historical GHRH(1-29)-NH2 fragment or a tetrasubstituted Modified GRF-style analogue with different stability assumptions. The primary endpoint might be acute GH response after a GHRH-side stimulus. The key COA checks are sequence, terminal identity, expected mass, purity, lot match, storage, and whether the CJC listing clearly states no-DAC status. The claim boundary is that either compound can be discussed as a research material without becoming hormone-replacement advice.

Scenario 2: a buyer is comparing CJC-1295 with DAC and CJC-1295 without DAC. This is mainly a time-profile comparison. DAC material belongs in sustained-exposure questions. No-DAC material belongs in shorter-pulse questions. The right design may include GH sampling windows, IGF-1 timing, washout expectations, and feedback interpretation. A product page that uses “CJC” loosely is not suitable for this comparison because the missing DAC status changes the experiment.

Scenario 3: a buyer is comparing Ipamorelin and GHRP-6. This is a GHSR-side comparison. Ipamorelin is often framed around a cleaner GH secretagogue profile, while GHRP-6 is useful when older-GHRP biology, appetite-linked signalling, or broader endocrine effects are part of the question. A serious protocol should decide whether ACTH, cortisol, prolactin, appetite, feeding state, or motility are confounders or intended endpoints. If those markers are not measured, the article should avoid confident claims about why one compound produced a downstream result.

Scenario 4: a buyer is using Tesamorelin as a clinical-reference comparator. Tesamorelin can add useful context because it has a regulated-drug history, but that history cuts both ways. It makes the evidence map more concrete, and it also makes overclaiming easier to spot. A page that uses Tesamorelin’s narrow clinical context to imply general anti-ageing or body-composition claims for RUO peptides is not reading the evidence conservatively.

Scenario 5: a buyer asks where MK-677 fits. MK-677 belongs in GHSR mechanism context, not in a peptide vial comparison. It may help explain sustained GHSR/GH/IGF-1 exposure literature, but route, duration, regulatory status, and small-molecule chemistry all differ from short lyophilised peptides. A Canadian RUO article should not use MK-677 as a ProductLink target when the live product path is unavailable, and it should not use MK-677 data to make claims about Ipamorelin or GHRP-6 without explaining the exposure difference.

These scenarios are intentionally conservative. They are also more useful than a generic ranking because they show the actual decision points a researcher or editor has to defend: mechanism, timing, endpoint, source quality, and claim boundary.

A final procurement note follows from all five scenarios: do not let convenience decide mechanism. A fixed blend can be convenient but harder to audit than separate vials. A long-acting analogue can look attractive because the signal lasts longer but may be wrong for a pulse model. A selective GHSR peptide can look cleaner than an older GHRP but still require appetite, stress-axis, and timing controls. A regulated-drug comparator can make a literature review stronger but cannot be used to launder RUO material into treatment language. In each case, the conservative path is the same: write the receptor lane, exposure profile, primary endpoint, and batch-documentation requirement before treating any supplier page as a candidate.

For editors, this also creates a useful internal-link rule. If a sentence compares two GH-axis compounds across lanes, link to this comparison guide. If a sentence focuses on one molecule’s identity, link to the dedicated compound guide. If a sentence discusses supplier evidence, link to the COA checklist or supplier scorecard. That keeps the archive navigable and keeps commercial intent separated from scientific claims.

FAQ#

References and further reading#

• Miller and Bowers, 2017, The Safety and Efficacy of Growth Hormone Secretagogues — open-access category review for GH secretagogue pharmacology and therapeutic-development context.
• Raun et al., 1998, Ipamorelin, the first selective growth hormone secretagogue — key endocrine selectivity paper comparing Ipamorelin with older GHRPs.
• Pulsatile secretion of GH persists during continuous stimulation by CJC-1295 — CJC-1295 DAC literature relevant to prolonged GHRH analogue exposure.
• Human GRF(1-29)-albumin bioconjugates and identification of CJC-1295 — preclinical analogue and albumin-binding context for CJC-1295.
• FDA label for Egrifta / tesamorelin — regulated-drug context that should not be generalized into broad wellness claims.
• Northern Compound follow-up pages: Sermorelin guide, CJC-1295 without DAC guide, CJC-1295 DAC guide, Ipamorelin guide, Tesamorelin guide, and GH pulsatility guide.

Bottom line#

A GH secretagogue comparison should not answer “which peptide is best?” It should answer a more useful question: which receptor lane, exposure profile, endpoint set, and supplier-documentation standard fit this research problem?

For Canadian buyers, that means starting with GHRH versus GHSR, then separating short-pulse tools from extended-exposure tools, then checking whether the current lot documentation supports the product page. ProductLink paths can help readers inspect live Lynx documentation for relevant materials such as Sermorelin, CJC-1295 without DAC, CJC-1295 with DAC, Ipamorelin, Tesamorelin, and GHRP-6. They do not replace COA review, lawful-use judgment, or protocol design.

The safe editorial move is also the useful one: mechanism first, endpoint second, supplier documentation third, claims last.